Entrada Therapeutics, Inc. TRDA R2K
Healthcare · Biotechnology · United States
Entrada Therapeutics, Inc., is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle, therapeutic candidates are based on a novel therapeutic; a robust development portfolio of genetic medicines for the potential treatment of neuromuscular and inherited retinal diseases. Its preclinical product includes ENTR-601-44; ENTR-601-45; and VX-670. The company was formerly known as CycloPorters, Inc., and changed its name to Entrada Therapeutics, Inc., in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.
READ MORE ›$7.07
-6.97% 1Y
Market & Price
Market Cap
$274.46M
Current Price
$7.07
High / Low (52W)
$16.03 / $5.02
Beta
-0.09
Valuation
Stock P/E
-
Industry PE
23.65
Forward P/E
-
PEG Ratio
-
Book Value
$8.50
Price to Book
0.83
P/S
47.83
EV/EBITDA
-0.29
Dividend Yield
-
Profitability & Returns
ROCE
-44.74%
ROE
-48.28%
ROA
-26.84%
Profit Margin
0.00%
Op Margin
-
EPS (Latest Qtr)
$-0.95
EPS (TTM)
$-4.00
Balance Sheet & Liquidity
Debt/Equity
0.18
Quick Ratio
13.40
Current Ratio
13.90
Debt
$49.75M
Total Assets
$377.38M
Current Assets
$306.25M
Working Capital
$281.80M
Ownership
Promoter Holding
12.31%
Chg in Prom Hold
-
FII / Inst Holding
78.41%
Chg in FII Hold
-
Financial Snapshot
Enterprise Value
$49.65M
Total Revenue (TTM)
$5.74M
EBITDA
$-172.56M
Free Cash Flow
$-75.38M
Operating Cash Flow
$-131.70M
Shares Outstanding
38.82M
Gross Margin
0.00%
Payout Ratio
0.00%
Growth (CAGR)
Revenue 5Y
-
Profit 5Y
-17.31%
Revenue (YoY)
-95.70%
Earnings (YoY)
-
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Earnings shrank at -17.3% CAGR over 5 years.
- Trading 55.9% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth
No fundamental data available for this stock.
Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | TRDA Entrada Therapeutics, Inc. R2K | 7.07 | - | $274.46M | - | -44.74% | -48.28% | - | -17.31% |
| 2 | LLY Eli Lilly and Company SPX | 1,105.00 | 39.21 | $985.37B | 0.63% | 38.44% | 107.46% | 31.69% | 48.96% |
| 3 | JNJ Johnson & Johnson SPX | 225.33 | 26.11 | $542.42B | 2.38% | 23.13% | 26.42% | 5.60% | 14.32% |
| 4 | UNH UnitedHealth Group Incorporated SPX | 380.31 | 28.66 | $345.38B | 2.32% | 9.60% | 12.18% | 11.35% | -15.69% |
| 5 | MRK Merck & Co., Inc. SPX | 118.72 | 33.44 | $293.22B | 2.86% | 20.66% | 18.94% | 3.12% | 7.93% |
| 6 | TMO Thermo Fisher Scientific Inc. SPX | 492.51 | 27.11 | $183.03B | 0.38% | 9.17% | 13.52% | -0.27% | -1.19% |
| 7 | AMGN Amgen Inc. NDXSPX | 336.79 | 23.42 | $181.77B | 2.99% | 18.02% | 101.32% | 11.77% | 5.58% |
| 8 | GILD Gilead Sciences, Inc. NDXSPX | 134.43 | 18.29 | $166.90B | 2.44% | 22.92% | 43.36% | 2.57% | 22.83% |
| 9 | ISRG Intuitive Surgical, Inc. NDXSPXAI | 424.64 | 51.53 | $150.39B | - | 15.96% | 17.23% | 17.39% | 29.26% |
Ad space
Quarterly Results
Figures in USD.
| Metric | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | 0 | 0 | 0 | 25.26M | 18.17M | 43.73M | 59.12M | 94.69M | 19.57M | 20.56M | 1.95M | 1.61M | 1.30M | 875.00K |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 42.35M | 48.80M | 48.66M | 43.51M | 43.18M |
| Operating Income | - | - | -6.97M | -8.39M | -9.91M | -14.36M | -22.15M | -23.58M | -25.94M | -5.78M | -16.30M | 14.01M | 21.11M | 53.42M | -21.66M | -21.79M | -46.85M | -47.05M | -42.21M | -42.30M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -20.84M | -45.81M | -45.82M | -41.32M | -41.50M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -17.35M | -42.92M | -43.48M | -39.07M | -39.68M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 178.00K | 654.00K | 92.00K | 38.00K |
| Net Income | -4.69M | -6.17M | -6.99M | -8.38M | -9.90M | -14.43M | -21.67M | -23.18M | -25.14M | -6.67M | -25.93M | 35.46M | 23.50M | 55.03M | -14.03M | -17.35M | -43.10M | -44.13M | -39.16M | -39.72M |
| Diluted EPS | - | - | -6.13 | -6.67 | -7.56 | -9.78 | -0.69 | -0.74 | -0.80 | -0.21 | -0.78 | 1.02 | 0.68 | 1.55 | -0.35 | -0.42 | -1.04 | -1.06 | -0.94 | -0.95 |
| R&D Expense | - | - | 5.70M | 6.22M | 6.83M | 10.51M | 15.72M | 16.25M | 18.96M | 23.10M | 26.30M | 22.19M | 28.61M | 32.03M | 31.26M | 32.07M | 37.88M | 38.36M | - | 33.05M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Revenue | - | - | 0 | 129.01M | 210.78M | 25.42M |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| Operating Expenses | - | - | 97.25M | 132.18M | 163.77M | 183.32M |
| Operating Income | -26.67M | - | -97.25M | -3.16M | 47.01M | -157.90M |
| EBITDA | - | - | -95.35M | -321.00K | 50.78M | -153.80M |
| Interest Expense | - | - | - | - | - | - |
| Pretax Income | - | - | -94.62M | 12.06M | 66.48M | -142.83M |
| Tax Provision | - | - | 0 | 18.74M | 859.00K | 924.00K |
| Net Income | -26.52M | - | -94.62M | -6.68M | 65.63M | -143.75M |
| Diluted EPS | -24.00 | - | -3.02 | -0.20 | 1.68 | -3.47 |
| R&D Expense | 21.10M | 35.93M | 66.61M | 99.88M | 125.31M | 142.27M |
Compounded Sales Growth
| 5 Years: | - |
| 1 Year: | -95.70% |
Compounded Profit Growth
| 5 Years: | -17.31% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | -6.97% |
| 6 Months: | -30.14% |
| 3 Months: | -40.74% |
| 1 Month: | -44.42% |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Total Assets | - | 43.53M | - | 252.06M | 469.19M | 526.32M | 377.38M |
| Current Assets | - | - | - | 209.88M | 369.77M | 440.04M | 306.25M |
| Cash & Equivalents | - | 39.05M | - | 45.16M | 67.60M | 101.21M | 90.39M |
| Inventory | - | - | - | - | - | - | - |
| Receivables | - | - | - | 0 | 5.88M | 3.68M | 1.18M |
| Total Liabilities | - | 3.36M | - | 39.50M | 226.83M | 97.64M | 71.25M |
| Current Liabilities | - | 3.36M | - | 21.97M | 158.80M | 39.48M | 24.45M |
| Long Term Debt | - | - | - | - | - | - | - |
| Total Debt | - | - | - | 25.94M | 68.23M | 59.21M | 50.93M |
| Total Equity | -15.52M | -41.49M | - | 212.55M | 242.36M | 428.68M | 306.13M |
| Shares Outstanding | - | - | - | 31.39M | 33.44M | 37.57M | 38.28M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -25.57M | - | -93.79M | 139.80M | -41.56M | -128.51M |
| Investing Cash Flow | -2.32M | - | -148.65M | -138.40M | -27.80M | 116.81M |
| Financing Cash Flow | 50.09M | - | 479.00K | 21.04M | 102.96M | 887.00K |
| Capital Expenditure | -2.32M | - | -2.89M | -5.61M | -3.16M | -1.04M |
| Free Cash Flow | -27.89M | - | -96.67M | 134.19M | -44.72M | -129.55M |
| Net Change in Cash | - | - | -241.96M | 22.45M | 33.61M | -10.82M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - |
| Operating Margin % | - | - | - | -2.5% | 22.3% | -621.1% |
| Net Margin % | - | - | - | -5.2% | 31.1% | -565.5% |
| ROE % | 63.9% | - | -44.5% | -2.8% | 15.3% | -47.0% |
| ROCE % | -66.4% | - | -42.3% | -1.0% | 9.7% | -44.7% |
Shareholding Pattern
Insiders
12.31%
Institutions
78.41%
Public Float
89.42%
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Baker Bros. Advisors, LP | 13.07% | 5.07M | $35.86M |
| 2 | 5AM Venture Management, LLC | 10.45% | 4.06M | $28.68M |
| 3 | Blackrock Inc. | 6.08% | 2.36M | $16.68M |
| 4 | TCG Crossover Management, LLC | 5.89% | 2.29M | $16.17M |
| 5 | Merck & Co., Inc. | 4.48% | 1.74M | $12.30M |
| 6 | Vanguard Capital Management LLC | 3.24% | 1.26M | $8.88M |
| 7 | Wellington Management Group, LLP | 2.67% | 1.03M | $7.32M |
| 8 | StepStone Group LP | 1.96% | 761.28K | $5.38M |
| 9 | Geode Capital Management, LLC | 1.72% | 667.35K | $4.72M |
| 10 | State Street Corporation | 1.38% | 533.80K | $3.77M |
Analyst View
Loading analyst coverage…
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for TRDA
No recent headlines available.